News Update

Life Science Company Addresses Antibiotic Resistance Problem

News Update
  ()
This firm's proprietary technology provides an alternative to antibiotic use in livestock production. read more >
News Update

Biotech Files Patent Application for Nitric Oxide Delivery Device

News Update
  ()
With this development, the company advances blood/plasma transfusion technology. read more >

Imprimis: Priming the Pumps for a Big 2019

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. read more >

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting

Research Report
  ()
A ROTH Capital Partners report relayed the contents of both presented abstracts. read more >

Catalysts Approaching for U.S. Developer of Cancer Therapeutics

Research Report
  ()
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. read more >
News Update

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer

Research Report
  ()
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. read more >
News Update

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says

News Update
  ()
This firm explains how its 15 years in drug development led to and supports this conclusion. read more >

Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation

Research Report
  ()
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. read more >
News Update

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment

News Update
  ()
With this achievement, the firm expands its potential partnering opportunities. read more >

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'

Research Report
  ()
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. read more >
Expert Investing Ideas

"PMN is looking to outlicense PMN310 after the Phase 1 study."

–André Uddin, Mackie Research Capital


"DRRX intends to start a NASH trial as soon as H1/19."

–Francois Brisebois, Laidlaw & Company


"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Catasys…Future's So Bright

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. read more >

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs

Contributed Opinion
  ()
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. read more >

Hemp Producer CV Sciences' Q3 Earnings Estimates--Our View

Contributed Opinion
  ()
Fincom Investment Partners previews Q3 earnings estimates for a company that it believes offers the best value in cannabis/hemp. read more >

Biotech to Expand Precision Medicine Services via New Partnership

Research Report
  ()
A Maxim Group report discussed the potential implications of this new collaboration in the field of personalized medicine and oncology. read more >